JP2024504331A5 - - Google Patents

Info

Publication number
JP2024504331A5
JP2024504331A5 JP2023544026A JP2023544026A JP2024504331A5 JP 2024504331 A5 JP2024504331 A5 JP 2024504331A5 JP 2023544026 A JP2023544026 A JP 2023544026A JP 2023544026 A JP2023544026 A JP 2023544026A JP 2024504331 A5 JP2024504331 A5 JP 2024504331A5
Authority
JP
Japan
Prior art keywords
cancer
use according
seq
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023544026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504331A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/072869 external-priority patent/WO2022156726A1/en
Publication of JP2024504331A publication Critical patent/JP2024504331A/ja
Publication of JP2024504331A5 publication Critical patent/JP2024504331A5/ja
Withdrawn legal-status Critical Current

Links

JP2023544026A 2021-01-21 2022-01-20 抗pd1抗体と組み合わせて抗tigit抗体を使用するがん処置方法 Withdrawn JP2024504331A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
CN2021073083 2021-01-21
CNPCT/CN2021/073083 2021-01-21
CNPCT/CN2021/073308 2021-01-22
CN2021073308 2021-01-22
CN2021074141 2021-01-28
CNPCT/CN2021/074141 2021-01-28
CNPCT/CN2021/074644 2021-02-01
CN2021074644 2021-02-01
CNPCT/CN2021/075310 2021-02-04
CN2021075310 2021-02-04
CNPCT/CN2021/091822 2021-05-05
CN2021091822 2021-05-05
CN2021109322 2021-07-29
CNPCT/CN2021/109322 2021-07-29
PCT/CN2022/072869 WO2022156726A1 (en) 2021-01-21 2022-01-20 Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies

Publications (2)

Publication Number Publication Date
JP2024504331A JP2024504331A (ja) 2024-01-31
JP2024504331A5 true JP2024504331A5 (https=) 2025-03-07

Family

ID=82548518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544026A Withdrawn JP2024504331A (ja) 2021-01-21 2022-01-20 抗pd1抗体と組み合わせて抗tigit抗体を使用するがん処置方法

Country Status (13)

Country Link
US (1) US20230391883A1 (https=)
EP (1) EP4281189A4 (https=)
JP (1) JP2024504331A (https=)
KR (1) KR20230158464A (https=)
CN (1) CN117177770A (https=)
AU (1) AU2022211109A1 (https=)
BR (1) BR112023014582A2 (https=)
CO (1) CO2023009626A2 (https=)
IL (1) IL304600A (https=)
MX (1) MX2023008597A (https=)
PE (1) PE20240659A1 (https=)
TW (1) TW202243691A (https=)
WO (1) WO2022156726A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115746144B (zh) * 2022-09-02 2026-01-02 安徽瀚海博兴生物技术有限公司 抗tigit-pd1双特异性抗体及其应用
WO2025002151A1 (zh) * 2023-06-27 2025-01-02 正大天晴药业集团股份有限公司 抗tigit抗体及其应用
CN121003695A (zh) * 2024-05-24 2025-11-25 百奥泰生物制药股份有限公司 抗tigit抗体和抗pd-1抗体联合治疗肿瘤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016000853A2 (pt) * 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
TWI877769B (zh) * 2017-12-30 2025-03-21 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
EP3746119A4 (en) * 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY
KR102184377B1 (ko) * 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
CN111836831A (zh) * 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
CN108840932B (zh) * 2018-04-28 2022-03-29 中国科学院微生物研究所 一种pd-1特异性抗体及其抗肿瘤应用
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途
CN111744013B (zh) * 2019-03-29 2022-07-26 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN112618577B (zh) * 2020-12-15 2023-07-25 深圳君拓生物科技有限公司 动物双歧杆菌在提高肿瘤免疫治疗应答中的作用

Similar Documents

Publication Publication Date Title
JP2024037894A5 (https=)
JP2023113893A5 (https=)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
JP2024504331A5 (https=)
JP2020019787A5 (https=)
JP2021521843A5 (https=)
JP2020528750A5 (https=)
JP2020514310A5 (https=)
JP2021524256A5 (https=)
JP2022116269A5 (https=)
CN109843927A (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
RU2018124319A (ru) Новые антитела к клаудину и способы их применения
JP2017535257A5 (https=)
RU2020127196A (ru) Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение
JP2023503396A5 (https=)
JP2022516351A5 (https=)
RU2018123709A (ru) Новые антитела для лечения онкологических заболеваний
JP2025038088A5 (https=)
JP2023543826A5 (https=)
JP2024540148A5 (https=)
JP2024533067A5 (https=)
JP2021512652A5 (https=)
JP2022519631A5 (https=)
JP2025511288A5 (https=)
JP2023502323A5 (https=)